Latest Editas Medicine News & Updates

See the latest news and media coverage for Editas Medicine. We track all announcements, press releases, and industry mentions in real time, all in one place.

Editas Medicine

Gene editing company developing CRISPR medicines

editasmedicine.com

Headquarters: Cambridge, United States
Founded year: 2013
Company type: Public company
Number of employees: 180–200
Industry: Pharmaceuticals

Last updated October 8

Latest news about Editas Medicine

In short: Editas Medicine advanced EDIT-401 toward first-in-human trials while cutting 65% of its workforce in a strategy shift.

Company announcements

October 8 Editas Medicine

Editas Medicine gets approval to start Phase 1/2 EDIT-401 trial in Australia

The company plans patient dosing this year, reporting initial safety data in Q1 2027, while new preclinical durability data presents at the AHA Scientific Sessions.

September 9 Editas Medicine

Editas Medicine grants stock options to new CMO Daniel Ory

The board approved a grant of up to 950,000 shares at $3.03 per share as an inducement for his employment, vesting over four years.

September 8 Editas Medicine

Editas Medicine appoints Dan Ory as Chief Medical Officer

Dr Ory leads clinical strategy and trials for the company genome editing programs across multiple therapeutic areas.

August 5 Editas Medicine

Editas Medicine reports Q2 2026 results and EDIT-401 progress

EDIT-401 is on track for CTN submission this month, with preclinical data showing ~90% LDL-C reduction; company raised $125M and extends cash runway into 2H 2028.

Media coverage

October 8 MSN

Editas Medicine gets clearance for first human trial of gene-editing drug - Wells Fargo sees potential for major value upside in 2027

In studies on non-human primates, EDIT-401 reduced bad cholesterol and other harmful blood fats by around 90%.

October 3 CGTLive

Editas Sells off iNK Preclinical Cell Therapy Program, Gene-Editing Technologies to Shoreline | CGTlive®

The addition of Editas Medicine’s novel gene editing SLEEK technology, combined with the use of a high efficiency and high fidelity proprietary CRISPR enzyme, and...

September 22 MarketScreener

Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5

Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell 2500 Growth Benchmark CI Jun. 29 Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell 2000 Growth Benchmark CI Jun. 29 Editas...

September 8 Yahoo Finance

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with...

Never miss news about Editas Medicine

Track Editas Medicine and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Editas Medicine competitors & trending companies

Browse news for competitors to Editas Medicine and other trending companies.